bluebird bio, Inc. (BLUE) Director Sells $95,950.00 in Stock
bluebird bio, Inc. (NASDAQ:BLUE) Director James Mandell sold 1,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $95.95, for a total transaction of $95,950.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at $95,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
bluebird bio, Inc. (NASDAQ:BLUE) traded up 0.47% during mid-day trading on Tuesday, hitting $97.05. 313,313 shares of the stock traded hands. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $123.75. The firm’s 50-day moving average price is $98.08 and its 200-day moving average price is $90.65. The firm’s market cap is $4.42 billion.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the company posted ($1.59) EPS. The business’s revenue was up 977.4% on a year-over-year basis. On average, equities analysts forecast that bluebird bio, Inc. will post ($6.78) earnings per share for the current fiscal year.
A number of research firms have issued reports on BLUE. Jefferies Group LLC restated a “buy” rating and set a $88.00 price target on shares of bluebird bio in a report on Friday. Morgan Stanley reiterated a “hold” rating on shares of bluebird bio in a research note on Wednesday, August 9th. BidaskClub upgraded shares of bluebird bio from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. BMO Capital Markets reiterated a “buy” rating and issued a $108.00 target price on shares of bluebird bio in a research note on Friday, August 4th. Finally, Sanford C. Bernstein started coverage on shares of bluebird bio in a research note on Thursday, July 27th. They issued a “market perform” rating and a $109.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. bluebird bio presently has an average rating of “Hold” and an average price target of $100.66.
Several hedge funds have recently modified their holdings of BLUE. QS Investors LLC increased its stake in shares of bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the period. Bank of Montreal Can boosted its position in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC bought a new position in bluebird bio during the second quarter worth about $184,000. SG Americas Securities LLC boosted its position in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after buying an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. bought a new position in bluebird bio during the second quarter worth about $210,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.